Compare Gilead Sciences, Inc. (GILD) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Gilead Sciences, Inc. trades at $149.39 (market cap $182.40B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.09 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| GILD | VEA | |
|---|---|---|
Market Cap | $182.40B | $323.80B |
Volume | 4,469,821 | 17,001,112 |
Sector | Health | — |
52-Week High | $155.80 | $73.79 |
52-Week Low | $116.74 | $58.90 |
Typical Hold Time | 111 Days | 131 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
VEA trades at $70.19, down 0.1% with a bearish technical signal. The ETF shows mixed institutional activity with some firms increasing positions while others reduced holdings. Recent news highlights VEA's competitive advantages including a low 0.03% expense ratio and higher dividend yield compared to peers. Technical indicators show oversold conditions with RSI at 28.4, suggesting potential for near-term bounce.
The outlook remains cautious given bearish technical momentum, though the fund's cost efficiency and developed market exposure provide long-term value. Key risks include global market volatility and currency fluctuations. Investors should monitor institutional flow trends and global economic developments for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
